Clearly, our synthetic method thatuses native antibodies does not hamper the biological activity ofthe parent mAbs, and the generated bispecific constructs retain theactivity of both the mAbs, activating the T lymphocytes against HER2+ cells, inducing tumor cell death even in the very low pMrange. The gene discussed is ERBB2; the disease is neoplasm.